Advertisement

AAO 2020 – Dry Eye Disease

AAO 2020: HBM9036 Nasal Spray for Dry Eye Disease

HBM9036 ophthalmic solution 0.25%,  also known as tanfanercept, a novel TNF-α inhibitor, is safe and effective for improving certain symptoms of dry eye disease, according to results of a phase 2 randomized, a double-blind...

AAO 2020: HBM9036 Nasal Spray for Dry Eye Disease

HBM9036 ophthalmic solution 0.25%,  also known as tanfanercept, a novel TNF-α inhibitor, is safe and effective for improving certain symptoms of dry eye disease, according to results of a phase 2 randomized, a double-blind...

Extending Survival for HIV-Infected Patients

Over the past few decades, advances in antiretroviral therapy (ART) have enabled many HIV-infected patients to live longer lives. Despite these successes, substantial avoidable losses in life expectancy of HIV-infected persons...

Loading

Advertisement

For latest news and updates
Email-id is invalid

Meeting Coverage